Mean age for starting anti-VEGF treatment for DMO was 61.5 years, with duration of diabetes at start of treatment being longer in patients with type 1 than type 2 diabetes (20.8 years versus 14.1 years). Here, VEGFA is linked to type 2 diabetes mellitus.